BioScrip Stock Price, News & Analysis (NASDAQ:BIOS)

$2.93 0.00 (0.00 %)
(As of 02/20/2018 02:47 AM ET)
Previous Close$2.93
Today's Range$2.90 - $2.99
52-Week Range$1.35 - $3.39
Volume392,683 shs
Average Volume936,859 shs
Market Capitalization$373.62 million
P/E Ratio-4.73
Dividend YieldN/A
Beta0.19

About BioScrip (NASDAQ:BIOS)

BioScrip logoBioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient's physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient's specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.

Receive BIOS News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Hospitals, Clinics & Primary Care Services
Sub-IndustryHealth Care Services
SectorHealthcare
SymbolNASDAQ:BIOS
CUSIP09069N10
Phone+1-720-6975200

Debt

Debt-to-Equity Ratio-6.11%
Current Ratio1.91%
Quick Ratio1.60%

Price-To-Earnings

Trailing P/E Ratio-4.7258064516129
Forward P/E Ratio-4.65
P/E GrowthN/A

Sales & Book Value

Annual Sales$935.59 million
Price / Sales0.40
Cash FlowN/A
Price / CashN/A
Book Value($0.27) per share
Price / Book-10.85

Profitability

Trailing EPS($0.62)
Net Income$-41,500,000.00
Net Margins-8.42%
Return on EquityN/A
Return on Assets-8.01%

Miscellaneous

Employees2,540
Outstanding Shares127,520,000

BioScrip (NASDAQ:BIOS) Frequently Asked Questions

What is BioScrip's stock symbol?

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

How were BioScrip's earnings last quarter?

BioScrip Inc (NASDAQ:BIOS) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.10) by $0.02. The company earned $198.70 million during the quarter, compared to analyst estimates of $202.91 million. The firm's revenue was down 11.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.12) EPS. View BioScrip's Earnings History.

When will BioScrip make its next earnings announcement?

BioScrip is scheduled to release their next quarterly earnings announcement on Thursday, March, 1st 2018. View Earnings Estimates for BioScrip.

Where is BioScrip's stock going? Where will BioScrip's stock price be in 2018?

3 equities research analysts have issued twelve-month price targets for BioScrip's stock. Their predictions range from $3.50 to $4.00. On average, they expect BioScrip's share price to reach $3.83 in the next twelve months. View Analyst Ratings for BioScrip.

What are Wall Street analysts saying about BioScrip stock?

Here are some recent quotes from research analysts about BioScrip stock:

  • 1. According to Zacks Investment Research, "BioScrip exited the third quarter on a dismal note, with earnings and revenues missing the Zacks Consensus Estimate. We are encouraged by the company’s recent progress, courtesy of its new multi-faceted CORE plan to improve the financial position. We are also upbeat about the company’s completion of the UnitedHealthcare contract transition and expectations of strong core revenue growth. Accordingly, over the last six months, BioScrip has been trading above the broader industry. On the flip side, a competitive landscape continues to be a major dampener. Also, management’s slashed guidance for 2017 adds to our concerns." (1/10/2018)
  • 2. Jefferies Group LLC analysts commented, "We are incrementally more positive on BIOS following better-than-expected 4Q results. Growth in Core revenues is progressing according to plan & expense initiatives should offset a majority of the headwind from the 21st Century Cures Act. Accelerating EBITDA growth throughout 2017 should provide investors with increasing confidence in BIOS ability to reduce debt leverage to more normalized levels (~6x) by YE17 & put BIOS on a path to >$80MM of EBITDA in 2018." (3/6/2017)

Who are some of BioScrip's key competitors?

Who are BioScrip's key executives?

BioScrip's management team includes the folowing people:

  • Daniel E. Greenleaf, President, Chief Executive Officer, Director (Age 51)
  • Stephen M. Deitsch, Chief Financial Officer, Senior Vice President, Treasurer (Age 45)
  • Harriet Booker, Chief Operating Officer, Senior Vice President (Age 51)
  • Betty Y Jang, Senior Vice President, Chief Compliance Officer (Age 47)
  • Danny Claycomb, Senior Vice President - Revenue Cycle Management
  • Tony Lopez, Vice President, Chief Accounting Officer, Controller (Age 51)
  • Kathryn M. Stalmack, General Counsel
  • Scott J. Davido, Chief Implementation Officer (Age 48)
  • Michael G. Bronfein CPA, Director (Age 60)
  • Steven Neumann, Director

Who owns BioScrip stock?

BioScrip's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (12.25%), Gabelli Funds LLC (8.12%), BlackRock Inc. (5.16%), Deutsche Bank AG (2.45%), Alta Fundamental Advisers LLC (2.35%) and Royce & Associates LP (1.43%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.

Who sold BioScrip stock? Who is selling BioScrip stock?

BioScrip's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Two Sigma Investments LP, California Public Employees Retirement System, Gilder Gagnon Howe & Co. LLC, Deutsche Bank AG, Alta Fundamental Advisers LLC, Continental Advisors LLC and TIAA CREF Investment Management LLC. Company insiders that have sold BioScrip company stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.

Who bought BioScrip stock? Who is buying BioScrip stock?

BioScrip's stock was bought by a variety of institutional investors in the last quarter, including Royce & Associates LP, BlackRock Inc., Gabelli Funds LLC, Two Sigma Advisers LP, MetLife Investment Advisors LLC, Wells Fargo & Company MN and Gotham Asset Management LLC. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, R Carter Pate and Stephen Deitsch. View Insider Buying and Selling for BioScrip.

How do I buy BioScrip stock?

Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioScrip's stock price today?

One share of BioScrip stock can currently be purchased for approximately $2.93.

How big of a company is BioScrip?

BioScrip has a market capitalization of $373.62 million and generates $935.59 million in revenue each year. The company earns $-41,500,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis. BioScrip employs 2,540 workers across the globe.

How can I contact BioScrip?

BioScrip's mailing address is 1600 Broadway Ste 950, DENVER, CO 80202-4970, United States. The company can be reached via phone at +1-720-6975200 or via email at [email protected]


MarketBeat Community Rating for BioScrip (BIOS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  182 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  310
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

BioScrip (NASDAQ:BIOS) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.83$3.83$3.75$3.94
Price Target Upside: 44.65% upside44.65% upside81.16% upside36.25% upside

BioScrip (NASDAQ:BIOS) Consensus Price Target History

Price Target History for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ:BIOS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/21/2017SunTrust BanksSet Price TargetBuy$4.00HighView Rating Details
8/10/2017Jefferies GroupReiterated RatingBuy$3.00 -> $4.00HighView Rating Details
6/26/2017Barrington ResearchBoost Price TargetOutperform$3.50HighView Rating Details
1/3/2017Lake Street CapitalInitiated CoverageBuy$4.50N/AView Rating Details
3/5/2016StephensReiterated RatingBuyN/AView Rating Details
(Data available from 2/20/2016 forward)

Earnings

BioScrip (NASDAQ:BIOS) Earnings History and Estimates Chart

Earnings by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ BIOS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/1/2018($0.08)N/AView Earnings Details
11/2/2017Q3 2017($0.10)($0.12)$202.91 million$198.70 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.10)($0.11)$220.05 million$218.11 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.12)($0.16)$230.23 million$217.80 millionViewListenView Earnings Details
3/3/2017Q4 2016($0.08)($0.08)$236.67 million$240.10 millionViewListenView Earnings Details
11/7/2016Q3($0.05)($0.12)$223.26 million$224.50 millionViewListenView Earnings Details
8/8/2016Q216($0.09)($0.08)$229.58 million$232.50 millionViewListenView Earnings Details
5/5/2016Q1($0.12)($0.17)$232.38 million$238.50 millionViewListenView Earnings Details
3/2/2016Q4($0.08)($0.13)$238.30 million$243.75 millionViewListenView Earnings Details
11/4/2015Q315($0.10)($0.19)$229.89 million$247.20 millionViewListenView Earnings Details
8/10/2015Q215($0.11)($0.02)$269.38 million$262.40 millionViewListenView Earnings Details
5/7/2015Q115($0.08)($0.19)$259.60 million$261.70 millionViewListenView Earnings Details
3/2/2015Q414($0.02)($0.72)$259.62 million$253.70 millionViewListenView Earnings Details
11/5/2014Q314$0.02($0.45)$240.08 million$244.00 millionViewListenView Earnings Details
8/6/2014Q214($0.05)($0.10)$233.70 million$247.10 millionViewListenView Earnings Details
5/8/2014Q114($0.04)($0.17)$222.65 million$239.60 millionViewListenView Earnings Details
2/26/2014Q413$0.02$0.02$237.58 million$243.50 millionViewListenView Earnings Details
11/6/2013Q3 2013$0.01$0.02$205.09 million$208.88 millionViewN/AView Earnings Details
8/7/2013Q2 2013$0.04$0.13$206.47 million$190.73 millionViewListenView Earnings Details
5/8/2013Q1 2013$0.02$0.04$189.36 million$199.07 millionViewListenView Earnings Details
3/11/2013Q4 2012$0.01$0.04$173.87 million$180.70 millionViewListenView Earnings Details
11/7/2012Q312($0.01)($0.01)$159.86 million$170.36 millionViewN/AView Earnings Details
8/8/2012($0.01)($0.07)ViewN/AView Earnings Details
5/9/2012($0.01)($0.05)ViewN/AView Earnings Details
3/9/2012$0.09$0.12ViewN/AView Earnings Details
11/8/2011$0.09$0.10ViewN/AView Earnings Details
8/8/2011$0.08$0.10ViewN/AView Earnings Details
5/3/2011($0.01)$0.05ViewN/AView Earnings Details
3/11/2011$0.04($1.25)ViewN/AView Earnings Details
11/2/2010Q3 2010$0.09$0.05ViewN/AView Earnings Details
7/30/2010Q2 2010$0.09$0.07ViewN/AView Earnings Details
4/30/2010Q1 2010$0.07($0.01)ViewN/AView Earnings Details
2/26/2010Q4 2009$0.10$0.03ViewN/AView Earnings Details
10/30/2009Q3 2009$0.10$0.14ViewN/AView Earnings Details
7/30/2009Q2 2009$0.06$0.11ViewN/AView Earnings Details
4/30/2009Q1 2009$0.04$0.08ViewN/AView Earnings Details
3/3/2009Q4 2008$0.05$0.09ViewN/AView Earnings Details
11/4/2008Q3 2008$0.05$0.06ViewN/AView Earnings Details
7/31/2008Q2 2008$0.03$0.04ViewN/AView Earnings Details
5/2/2008Q1 2008$0.05($0.01)ViewN/AView Earnings Details
3/4/2008Q4 2007$0.04$0.06ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

BioScrip (NASDAQ:BIOS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.10)($0.06)($0.08)
Q2 20182($0.07)($0.05)($0.06)
Q3 20182($0.06)($0.03)($0.05)
Q4 20182($0.01)$0.00($0.01)
Q1 20191($0.04)($0.04)($0.04)
Q2 20191($0.03)($0.03)($0.03)
Q3 20191($0.02)($0.02)($0.02)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for BioScrip (NASDAQ:BIOS)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

BioScrip (NASDAQ BIOS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.80%
Institutional Ownership Percentage: 85.51%
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)
Insider Trades by Quarter for BioScrip (NASDAQ:BIOS)

BioScrip (NASDAQ BIOS) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/9/2017Daniel E GreenleafCEOBuy15,000$2.03$30,450.0031,000View SEC Filing  
11/9/2017Stephen DeitschCFOBuy10,000$2.03$20,300.0010,000View SEC Filing  
9/15/2017Michael G BronfeinDirectorSell27,000$2.69$72,630.00129,669View SEC Filing  
9/7/2017Coliseum Capital Management, LDirectorSell2,846,941$2.93$8,341,537.13View SEC Filing  
8/17/2017Coliseum Capital Management, LDirectorSell886,478$3.08$2,730,352.24View SEC Filing  
11/11/2016Jeffrey M KregerCFOBuy10,000$1.32$13,200.0022,628View SEC Filing  
11/10/2016Daniel E GreenleafCEOBuy16,000$1.30$20,800.0016,000View SEC Filing  
11/10/2016R Carter PateDirectorBuy20,000$1.30$26,000.0084,000View SEC Filing  
6/22/2016Coliseum Capital Management, LDirectorBuy4,200,000$2.00$8,400,000.00View SEC Filing  
6/17/2016David W GoldingDirectorBuy12,500$2.48$31,000.0042,500View SEC Filing  
8/24/2015Coliseum Capital Management, LDirectorBuy789,503$1.88$1,484,265.64View SEC Filing  
8/21/2015Coliseum Capital Management, LDirectorBuy632,907$1.81$1,145,561.67View SEC Filing  
8/18/2015David W GoldingDirectorBuy20,000$1.54$30,800.0030,000View SEC Filing  
3/16/2015Richard M SmithCEOBuy5,000$4.27$21,350.00View SEC Filing  
3/12/2015Yon JordenDirectorBuy5,000$3.47$17,350.00View SEC Filing  
6/16/2014Myron Z HolubiakDirectorSell5,000$7.94$39,700.00View SEC Filing  
5/14/2014Yon JordenDirectorBuy5,000$7.21$36,050.0015,000View SEC Filing  
8/30/2013Daniel ColucciVPSell18,500$12.40$229,400.002,580View SEC Filing  
8/28/2013David HubersDirectorSell11,200$12.23$136,976.0071,360View SEC Filing  
8/28/2013Patricia BoguszVPSell39,687$11.94$473,862.785,088View SEC Filing  
8/19/2013Kohlberg Management V, LlcInsiderSell6,895,873$13.00$89,646,349.00View SEC Filing  
7/19/2013Myron Z HolubiakDirectorSell31,200$16.34$509,808.00View SEC Filing  
11/13/2012Stuart A SamuelsDirectorSell11,200$9.66$108,192.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

BioScrip (NASDAQ BIOS) News Headlines

Source:
DateHeadline
BioScrip (BIOS) Downgraded to Hold at BidaskClubBioScrip (BIOS) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - February 17 at 3:16 PM
BioScrip Inc (BIOS) Receives Consensus Rating of "Buy" from AnalystsBioScrip Inc (BIOS) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - February 17 at 3:20 AM
$171.79 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter$171.79 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter
www.americanbankingnews.com - February 12 at 2:08 AM
BioScrip Announces US Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019 - Business Wire (press release)BioScrip Announces US Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019 - Business Wire (press release)
www.businesswire.com - February 11 at 3:50 PM
BioScrip (BIOS) Raised to "Buy" at BidaskClubBioScrip (BIOS) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - February 10 at 12:12 PM
BioScrip Announces U.S. Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019BioScrip Announces U.S. Congress Passage of Medicare Home Infusion Transition Benefit, Effective 2019
finance.yahoo.com - February 9 at 9:14 AM
One Thing To Consider Before Buying BioScrip Inc (NASDAQ:BIOS)One Thing To Consider Before Buying BioScrip Inc (NASDAQ:BIOS)
finance.yahoo.com - January 31 at 9:10 AM
BioScrip (BIOS) Cut to "Hold" at BidaskClubBioScrip (BIOS) Cut to "Hold" at BidaskClub
www.americanbankingnews.com - January 27 at 3:58 PM
 Brokerages Anticipate BioScrip Inc (BIOS) Will Announce Quarterly Sales of $171.79 Million Brokerages Anticipate BioScrip Inc (BIOS) Will Announce Quarterly Sales of $171.79 Million
www.americanbankingnews.com - January 26 at 1:44 AM
-$0.08 Earnings Per Share Expected for BioScrip Inc (BIOS) This Quarter-$0.08 Earnings Per Share Expected for BioScrip Inc (BIOS) This Quarter
www.americanbankingnews.com - January 24 at 11:10 PM
BioScrip Inc (BIOS) Given Average Recommendation of "Buy" by AnalystsBioScrip Inc (BIOS) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - January 23 at 3:46 AM
What Can We Expect for BioScrip Inc (NASDAQ:BIOS) Moving Forward?What Can We Expect for BioScrip Inc (NASDAQ:BIOS) Moving Forward?
finance.yahoo.com - January 19 at 5:46 PM
BioScrip Inc to Post FY2018 Earnings of ($0.22) Per Share, Barrington Research Forecasts (BIOS)BioScrip Inc to Post FY2018 Earnings of ($0.22) Per Share, Barrington Research Forecasts (BIOS)
www.americanbankingnews.com - January 10 at 4:12 PM
BioScrip (BIOS) Upgraded by Zacks Investment Research to "Hold"BioScrip (BIOS) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 10 at 3:52 PM
BioScrip Announces Availability of HEMLIBRA® for Hemophilia Patients - GlobeNewswire (press release)BioScrip Announces Availability of HEMLIBRA® for Hemophilia Patients - GlobeNewswire (press release)
globenewswire.com - January 8 at 9:58 AM
BioScrip Announces Availability of HEMLIBRA® for Hemophilia PatientsBioScrip Announces Availability of HEMLIBRA® for Hemophilia Patients
finance.yahoo.com - January 8 at 9:58 AM
BioScrip Inc (NASDAQ:BIOS): Does 8.3% Earnings Drop In A Year Reflect The Long-Term Trend?BioScrip Inc (NASDAQ:BIOS): Does 8.3% Earnings Drop In A Year Reflect The Long-Term Trend?
finance.yahoo.com - December 29 at 5:10 PM
BioScrip Inc (BIOS) Given Consensus Recommendation of "Hold" by AnalystsBioScrip Inc (BIOS) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - December 29 at 3:56 AM
ETFs with exposure to BioScrip, Inc. : December 28, 2017ETFs with exposure to BioScrip, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 3:52 PM
Zacks: Analysts Expect BioScrip Inc (BIOS) Will Announce Earnings of -$0.08 Per ShareZacks: Analysts Expect BioScrip Inc (BIOS) Will Announce Earnings of -$0.08 Per Share
www.americanbankingnews.com - December 22 at 1:22 PM
BioScrip (BIOS) Rating Reiterated by SunTrust BanksBioScrip (BIOS) Rating Reiterated by SunTrust Banks
www.americanbankingnews.com - December 21 at 9:20 PM
BioScrip (BIOS) vs. Its Competitors Financial ComparisonBioScrip (BIOS) vs. Its Competitors Financial Comparison
www.americanbankingnews.com - December 15 at 1:34 PM
BioScrip (BIOS) vs. Its Competitors Head-To-Head AnalysisBioScrip (BIOS) vs. Its Competitors Head-To-Head Analysis
www.americanbankingnews.com - December 15 at 11:10 AM
Have Investors Already Priced In BioScrip Inc’s (NASDAQ:BIOS) Growth?Have Investors Already Priced In BioScrip Inc’s (NASDAQ:BIOS) Growth?
finance.yahoo.com - December 14 at 5:46 PM
Reviewing BioScrip (BIOS) and Its PeersReviewing BioScrip (BIOS) and Its Peers
www.americanbankingnews.com - December 14 at 5:40 PM
Critical Survey: BioScrip (BIOS) versus Its RivalsCritical Survey: BioScrip (BIOS) versus Its Rivals
www.americanbankingnews.com - December 14 at 1:18 AM
Head to Head Review: BioScrip (BIOS) and Its CompetitorsHead to Head Review: BioScrip (BIOS) and Its Competitors
www.americanbankingnews.com - December 13 at 5:36 PM
Analyzing BioScrip (BIOS) and Its PeersAnalyzing BioScrip (BIOS) and Its Peers
www.americanbankingnews.com - December 12 at 5:16 PM
Comparing BioScrip (BIOS) & Its CompetitorsComparing BioScrip (BIOS) & Its Competitors
www.americanbankingnews.com - December 11 at 11:22 PM
ETFs with exposure to BioScrip, Inc. : December 11, 2017ETFs with exposure to BioScrip, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 5:27 PM
Critical Contrast: BioScrip (BIOS) versus Its RivalsCritical Contrast: BioScrip (BIOS) versus Its Rivals
www.americanbankingnews.com - December 8 at 5:14 PM
Comparing AMERIGROUP (AGP) & BioScrip (BIOS)Comparing AMERIGROUP (AGP) & BioScrip (BIOS)
www.americanbankingnews.com - December 7 at 5:50 AM
Financial Comparison: BioScrip (BIOS) & The CompetitionFinancial Comparison: BioScrip (BIOS) & The Competition
www.americanbankingnews.com - December 7 at 1:22 AM
BioScrip (BIOS) & Its Rivals Head to Head AnalysisBioScrip (BIOS) & Its Rivals Head to Head Analysis
www.americanbankingnews.com - December 6 at 9:58 AM
 Analysts Anticipate BioScrip, Inc. (BIOS) Will Post Quarterly Sales of $171.79 Million Analysts Anticipate BioScrip, Inc. (BIOS) Will Post Quarterly Sales of $171.79 Million
www.americanbankingnews.com - December 6 at 5:00 AM
 Brokerages Expect BioScrip, Inc. (BIOS) to Announce -$0.08 Earnings Per Share Brokerages Expect BioScrip, Inc. (BIOS) to Announce -$0.08 Earnings Per Share
www.americanbankingnews.com - December 4 at 5:12 PM
BioScrip, Inc. (BIOS) Receives Consensus Recommendation of "Hold" from AnalystsBioScrip, Inc. (BIOS) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - December 4 at 3:46 AM
Analyzing BioScrip (BIOS) and The CompetitionAnalyzing BioScrip (BIOS) and The Competition
www.americanbankingnews.com - December 1 at 11:38 AM
Critical Contrast: BioScrip (BIOS) vs. The CompetitionCritical Contrast: BioScrip (BIOS) vs. The Competition
www.americanbankingnews.com - December 1 at 3:32 AM
BioScrip (BIOS) Stock Rating Upgraded by ValuEngineBioScrip (BIOS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - November 30 at 11:02 PM
ETFs with exposure to BioScrip, Inc. : November 30, 2017ETFs with exposure to BioScrip, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 5:11 PM
Pre-market Technical Scan on Healthcare Equities -- Anthem, Cigna, Amedisys, and BioScrip - PR Newswire (press release)Pre-market Technical Scan on Healthcare Equities -- Anthem, Cigna, Amedisys, and BioScrip - PR Newswire (press release)
www.prnewswire.com - November 30 at 10:04 AM
BioScrip to Host Meetings at the Mizuho Investor Conference - GlobeNewswire (press release)BioScrip to Host Meetings at the Mizuho Investor Conference - GlobeNewswire (press release)
globenewswire.com - November 30 at 10:04 AM
BioScrip to Host Meetings at the Mizuho Investor ConferenceBioScrip to Host Meetings at the Mizuho Investor Conference
finance.yahoo.com - November 30 at 10:04 AM
Analyzing BioScrip (BIOS) & Its PeersAnalyzing BioScrip (BIOS) & Its Peers
www.americanbankingnews.com - November 30 at 9:30 AM
BioScrip Announces Additions to Senior Leadership Team - GlobeNewswire (press release)BioScrip Announces Additions to Senior Leadership Team - GlobeNewswire (press release)
globenewswire.com - November 29 at 5:34 PM
BioScrip (BIOS) Names Harriet Booker as COOBioScrip (BIOS) Names Harriet Booker as COO
www.streetinsider.com - November 29 at 9:44 AM
Head to Head Analysis: BioScrip (BIOS) & Its RivalsHead to Head Analysis: BioScrip (BIOS) & Its Rivals
www.americanbankingnews.com - November 29 at 1:14 AM
Reviewing BioScrip (BIOS) & Its CompetitorsReviewing BioScrip (BIOS) & Its Competitors
www.americanbankingnews.com - November 28 at 11:24 PM
BioScrip Announces Additions to Senior Leadership TeamBioScrip Announces Additions to Senior Leadership Team
finance.yahoo.com - November 28 at 5:13 PM

SEC Filings

BioScrip (NASDAQ:BIOS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

BioScrip (NASDAQ:BIOS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

BioScrip (NASDAQ BIOS) Stock Chart for Tuesday, February, 20, 2018

Loading chart…

This page was last updated on 2/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.